266
Participants
Start Date
March 21, 2018
Primary Completion Date
November 26, 2018
Study Completion Date
November 26, 2018
VP-102 - Cantharidin, Topical Film Forming Solution
VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
Placebo -Topical Film Forming Solution without VP-102
Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
Kings County Hospital, Brooklyn
University North Carolina Dermatology Center, Chapel Hill
Skin Research Institute, Coral Gables
Study Protocol, Inc.,, Boynton Beach
Olympian Clinical Research, Tampa
ASCLEPES Research Center, Spring Hill
Alabama Clinical Therapeutics, Birmingham
Southeastern Pediatric Associates, Dothan
Holston Medical Group, Bristol
The Pediatric Associates of Fairfield, Inc, Fairfield
Clarkston Skin Research, Clarkston
Summit Dermatology, Oakbrook Terrace
St Louis Children's Hospital, St Louis
Arlington Research Center, Arlington
Midwest Children's Hospital, Lincoln
Applied Research Center of Arkansas, Little Rock
ACRC Trials Plano Pediatrics, Plano
Center for Skin Research, Houston
Collaborators (1)
Instat Consulting, Inc.
OTHER
Paidion Research, Inc.
INDUSTRY
Database Integrations, Inc.
INDUSTRY
Verrica Pharmaceuticals Inc.
INDUSTRY